NAGIOS: RODERIC FUNCIONANDO

Monitoring of Trough Plasma Ganciclovir Levels and Peripheral Blood Cytomegalovirus (CMV)-Specific CD8+ T Cells To Predict CMV DNAemia Clearance in Preemptively Treated Allogeneic Stem Cell Transplant Recipients

Repositori DSpace/Manakin

dc.contributor.author	Giménez Quiles, Estela Berenice	es_ES
dc.contributor.author	Solano Vercet, Carlos	es_ES
dc.contributor.author	Azanza, José Ramón	es_ES
dc.contributor.author	Amat Martínez, Paula	es_ES
dc.contributor.author	Navarro Ortega, David	es_ES
dc.date.accessioned	2015-06-18T07:02:05Z
dc.date.available	2015-06-18T07:02:05Z
dc.date.issued	2014	es_ES
dc.identifier.citation	Antimicrobial Agents and Chemotherapy Vol. 58 Issue 9: pp. 5602-5605	es_ES
dc.identifier.uri	http://hdl.handle.net/10550/44423
dc.description.abstract	It is uncertain whether monitoring plasma ganciclovir (GCV) levels is useful in predicting cytomegalovirus (CMV) DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients. In this observational study, including 13 episodes of CMV DNAemia treated with intravenous (i.v.) GCV or oral valganciclovir, we showed that monitoring trough plasma GCV levels does not reliably predict response to therapy. Rather, immunological monitoring (pp65 and immediate-early [IE]-1-specific gamma interferon [IFN-γ]-producing CD8+ T cells) appeared to perform better for this purpose.	es_ES
dc.title	Monitoring of Trough Plasma Ganciclovir Levels and Peripheral Blood Cytomegalovirus (CMV)-Specific CD8+ T Cells To Predict CMV DNAemia Clearance in Preemptively Treated Allogeneic Stem Cell Transplant Recipients	es_ES
dc.type	journal article	es_ES
dc.identifier.doi	10.1128/AAC.02953-14	es_ES
dc.identifier.idgrec	101010	es_ES